The ReProgram

🎬 EPISODE OVERVIEW

Can we reverse aging? We examine what recent clinical announcements actually prove about the state of human longevity science.Recent reports regarding partial cellular reprogramming have sparked debate about the potential for human age reversal. We break down the distinction between clinical benefit and actual tissue rejuvenation, focusing on what early findings from human trials really indicate. By separating marketing claims from biological reality, we clarify how these interventions affect cellular function.Understanding the limits of current research is vital for anyone interested in healthy aging. We analyze why improvements in specific metrics, such as visual-field tests, do not necessarily equate to a universal reset of the aging process. This assessment provides a grounded look at how we measure progress in the field of longevity and what future experiments must demonstrate to validate these early observations.If you value longevity science without the hype, subscribe to The ReProgram.

🔑 KEYWORDS

Partial Reprogramming • ER-100 • OSK • Epigenetics • Glaucoma • Cell Identity • Aging Clocks • Healthspan

📌 KEY TAKEAWAYS

• Partial reprogramming aims to change cellular state while preserving specialized function.

• Early observations in three participants justify further study, not a conclusion of human age reversal.

• Improvement at visual-field test locations is not a percentage gain in overall vision.

• Control of gene expression does not establish that every downstream effect is reversible.

• Durable patient benefit, controlled comparisons, and replication matter more than a younger-looking test alone.

🎙️ THE REPROGRAM PERSPECTIVE

A treatment can be a major medical advance without proving that aging has been reversed.The goal is useful function, resilience, and more time living well. Hope and demanding scientific questions belong together.

⏱️ CHAPTERS

00:00 Can we reverse aging—and what would count?

01:30 The ReProgram opening

01:38 Partial reprogramming and the evidence cutoff

02:18 Cell identity and the epigenome

03:22 Yamanaka factors and pluripotency

04:23 The challenge of partial reprogramming

05:16 What mouse studies establish

06:01 Beyond a universal reset button

06:51 Vision, OSK, and preclinical evidence

08:42 ER-100 and early human observations

10:30 Understanding the visual-field measurement

11:49 What a small early trial can tell us

12:50 Variability, learning, and alternative explanations

15:39 Cell identity and safety

16:16 Delivery, control, and reversibility

17:32 Company announcements and complete evidence

18:05 Clinical benefit versus tissue rejuvenation

19:56 Broader healthspan claims

20:35 Aging clocks and meaningful outcomes

22:27 What would strengthen the evidence?

24:26 Hope, rigor, and the next experiments

25:23 Closing thoughts and subscribe

📝 NOTES AND REFERENCES

1. Takahashi & Yamanaka. Induction of pluripotent stem cells (Cell, 2006).https://doi.org/10.1016/j.cell.2006.07.024

2. Ocampo et al. In vivo partial reprogramming (Cell, 2016).https://doi.org/10.1016/j.cell.2016.11.052

3. Lu et al. Reprogramming to recover youthful epigenetic information and restore vision (Nature, 2020).https://doi.org/10.1038/s41586-020-2975-4

4. Life Biosciences. Interim company announcement, October 8, 2026; preliminary findings, not a full trial publication.https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/

5. ER-100 trial registration, NCT07290244.https://clinicaltrials.gov/study/NCT07290244

💬 JOIN THE CONVERSATION

What evidence would convince YOU that a treatment meaningfully rejuvenated human tissue—and what should the next study measure?Subscribe to The ReProgram for longevity biology without the hype.

https://www.youtube.com/@ReProgramPodcast

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Can you actually eat like a centenarian to extend your life? We examine the evidence behind dietary habits and aging.Dr. Paola Sebastiani joins us to discuss the complexities of longevity science and why the current diet of someone who has lived to 100 may not reflect the factors that helped them reach that age. We unpack how metabolomics provides clues about physiological decline, while emphasizing that a single blood marker does not establish cause and effect for long-term health.Our conversation addresses common myths regarding protein intake and the role of genetics in exceptional longevity. By analyzing the data from the New England Centenarian Study, we separate biological mechanisms from marketing claims to understand what truly supports healthy aging. We also look at the limitations of biological age tests and why standardization remains a critical challenge in current research.If you value longevity science without the hype, subscribe to The ReProgram for weekly evidence-based breakdowns. What is one belief about food and aging you would be willing to reconsider?

👤 ABOUT THE SPEAKER

Dr. Paola Sebastiani is a Professor at Tufts University School of Medicine and Director of the Tufts CTSI Biostatistics, Epidemiology, and Research Design Center. A biostatistician studying genetics and exceptional longevity, she and her group lead data analyses for the New England Centenarian Study.

Official profile: https://disc.tufts.edu/paola-sebastiani

🔑 KEYWORDS

Paola Sebastiani • Centenarians • Nutrition • Metabolomics • Protein • Healthy Aging • Longevity Genetics • Biological Age

📌 KEY TAKEAWAYS

• Metabolites offer clues about aging, but a blood marker does not by itself establish cause and effect.

• A centenarian’s current diet may differ from the diet they followed decades earlier. Longitudinal studies matter.

• Protein findings from animal studies do not automatically translate to older adults. Sebastiani also cautions against assuming more is always better.

• Centenarians are a diverse group; no single food or genetic explanation captures every path to exceptional longevity.

• Sebastiani emphasizes standardization and interpretation when discussing biological-age tests.

🎙️ THE REPROGRAM PERSPECTIVE

A longevity headline can turn an association into an apparent prescription. We need to ask who was studied, what was measured, and whether a finding predicts better health or simply accompanies it.The goal is to preserve health, function, and independence—not just chase a number.

⏱️ CHAPTERS

00:00 Should we eat like a centenarian?

00:58 Introducing Paola Sebastiani

01:57 An unexpected route into longevity research

03:56 The Cell Reports paper and metabolomics

06:04 Nutrition and the dark-chocolate connection

07:19 Why following people over time matters

09:01 Essential amino acids and dietary changes

14:12 What do centenarians eat?

18:31 Protein restriction versus aging well

20:39 Protein sources and pumpkin seeds

22:40 Dietary fats

23:26 Genes, nutrition, and longevity families

26:57 Centenarian misconceptions

27:43 Biological-age tests

28:57 Healthspan and longevity interventions

30:05 The unresolved genetics of longevity

31:08 Activity tracking and personal habits

33:21 What aging well means

34:20 Closing thoughts

📝 NOTES AND REFERENCES

1. Sebastiani P et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Reports (2024);43(11):114913.https://doi.org/10.1016/j.celrep.2024.114913Open-access paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11656345/

💬 JOIN THE CONVERSATION

What is one belief about food and aging you would be willing to reconsider?

Subscribe to The ReProgram for more conversations about livingwell.

https://www.youtube.com/@ReProgramPodcast

Longevity Biology Without the Hype

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Does your fish oil capsule deserve its reputation? In Episode 31, I review omega-3s for heart health, cognition, and healthy aging, then give five evidence scores and an overall C+.We examine VITAL, REDUCE-IT, STRENGTH, newer DHA research, aging clocks, and safety. Eating fish, taking supplements, and using prescription omega-3s are different questions.

🔑 KEYWORDS

Omega-3 • Fish Oil • EPA • DHA • Triglycerides • Cognition • Aging Clocks • Atrial Fibrillation • Longevity

📌 KEY TAKEAWAYS

• Triglyceride lowering: 5/5 at studied therapeutic doses.

• Routine cardiovascular prevention in generally healthy adults: 2/5. Prescription EPA in selected high-risk patients is a separate clinical decision.

• Preventing cognitive decline in generally healthy older adults: 1/5.

• Epigenetic aging clocks: 2/5. Small changes in clock estimates do not establish longer life.

• Extending human lifespan through routine supplementation: 1/5.

• Overall: C+ for routine OTC fish oil as a healthy-aging intervention; this is my assessment, not a mathematical average. Dose, formulation, and baseline risk matter.

🎙️ THE REPROGRAM PERSPECTIVE

A biological mechanism or improved test result is a starting point. Ask whether the evidence shows better health, function, or survival in people like you. Educational discussion; understand prescribed treatment with your clinician before making changes.

⏱️ CHAPTERS

00:00 What has fish oil earned?

00:55 The Scorecard framework

01:16 Fish, supplements, and prescription products

01:56 Read the EPA and DHA label

02:27 Triglycerides: the strongest evidence

03:43 VITAL and heart prevention

04:39 REDUCE-IT and prescription EPA0

5:50 STRENGTH and conflicting results

07:08 Brain health and the DHA trials

08:34 DO-HEALTH and aging clocks

09:59 Heart-rhythm risk and interactions

11:37 Five claims, five scores

13:22 The C+ verdict and its limits

14:27 Questions to ask about your supplement

15:31 Closing perspective

💬 JOIN THE CONVERSATION

If you take fish oil, what benefit are you hoping for—and does the evidence match that goal?

Subscribe to The ReProgram: https://www.youtube.com/@ReProgramPodcast

Longevity Biology Without the Hype.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Can a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation.

We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time

.👤 ABOUT THE SPEAKER

Dr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/

🔑 KEYWORDS

Steve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience

📌 KEY TAKEAWAYS

• Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks.

• Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation.

• Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet.

• Rejuvenation is connected to prevention: the aim is to preserve health before disease develops.

• A realistic path may focus on individual organs rather than a single treatment for the entire body.

🎙️ THE REPROGRAM PERSPECTIVE

Better measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function?

⏱️ CHAPTERS

00:00 Can we measure and reverse aging?

00:51 Introducing Steve Horvath

01:40 Reinventing a research career

05:28 Why are there so many aging clocks?

07:51 Bringing clocks into clinical practice

09:16 Evaluating age-reversal claims

11:31 Rejuvenation and prevention

14:37 What does rejuvenation mean?

16:26 One organ at a time

18:36 Lifestyle, testing, and perspective

20:57 Closing thoughts

📝 NOTES AND REFERENCES

Related papers featured in the edit:

1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r115

2. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-3

3. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans.

💬 JOIN THE CONVERSATION

What would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both?

Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcast

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

Why do some animals live so much longer than others—and what can they teach us about healthier human aging?In Episode 29 of The ReProgram, I sit down with Dr. Steve Austad to explore nature’s longevity clues, why women tend to outlive men, and what would count as convincing evidence that an intervention slows aging.We discuss aging “speedometers,” the difference between lifespan and healthspan, the case for funding geroscience, and how to evaluate biological-age claims without losing sight of enjoying life.

👤 ABOUT THE SPEAKER

Dr. Steven N. Austad is a Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, and Scientific Director of the American Federation for Aging Research. His research explores the comparative biology of aging, using differences among species to understand longevity and identify potential ways to preserve human health.Official profile: https://www.uab.edu/icar/about/icar-leadership/steven-n-austad-phd

🔑 KEYWORDS

Longevity • Comparative Biology • Steve Austad • Healthspan • Aging Rate Indicators • Biological Age • Geroscience • Sex Differences • DunedinPACE

📌 KEY TAKEAWAYS

• Long-lived animals offer clues about aging biology and potential directions for human research.

• A finding in animals is a starting point; demonstrating a meaningful benefit in people requires further testing.

• Measuring biological age and measuring the pace of aging are different questions. A change in a test result alone does not prove that an intervention slows aging.

• Healthspan puts the focus on maintaining function and quality of life.

• Evaluating longevity claims means asking what was measured, what changed, and whether the evidence supports the conclusion.

🎙️ THE REPROGRAM PERSPECTIVE

Nature shows that the pace of aging varies enormously across species. Understanding the biology behind those differences could reveal ways to preserve human health.For The ReProgram, the next step is to connect those clues to rigorous tests: does an intervention produce a reproducible improvement in function, resilience, or healthy years of life? Aging measurements are valuable when they help answer that question. The goal is more time living well, with evidence strong enough to guide our choices.

⏱️ CHAPTERS

00:00 What nature can teach us

00:28 The ReProgram

00:36 Introducing Steve Austad

01:23 Opossums and the origins of an aging scientist

02:44 What is aging?

03:43 Evolution and longevity

04:46 Learning from long-lived animals

07:24 Why women tend to live longer

12:03 What would count as evidence of slower aging?

13:13 From animal findings to human benefits

14:31 Aging clocks versus aging speedometers

18:49 Lifespan and healthspan

19:44 Lightning round: the XPRIZE

21:19 Funding aging research

22:43 Evaluating biological-age claims

24:01 Enjoying life while studying longevity

25:13 Closing thoughts

📝 NOTES AND REFERENCES

1. Austad SN, Kaeberlein M, Miller RA. Aging rate indicators and the search for anti-aging drugs. Frontiers in Science (2026).https://doi.org/10.3389/fsci.2026.1821393

2. Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife (2022);11:e73420.https://doi.org/10.7554/eLife.73420Clarification: DunedinPACE uses DNA methylation to estimate the pace of aging. The on-screen explanation clarifies the interview’s reference to an RNA marker.

3. XPRIZE Healthspan — official competition information:https://www.xprize.org/competitions/healthspan

💬 JOIN THE CONVERSATION

What would convince YOU that a treatment truly slows aging: a biological-age test, better physical function, or something else?

Tell us which result matters most—and why.If you value longevity science without the hype, subscribe to The ReProgram.https://www.youtube.com/@ReProgramPodcast

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEW

The Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related decline.This initiative represents a distinct pivot in geroscience research, moving beyond single-pathway hypotheses to look at systemic biological markers. We analyze the scope of these projects to see which are likely to yield clinical outcomes and which remain preliminary explorations. Understanding the biology of aging remains a complex challenge, but this consortium provides a structural framework for how we might eventually mitigate chronic disease.

🔑 KEYWORDS

Longevity • Healthspan • Aging Biology • NIH • NIA • Longevity Consortium • Nik Schork • Centenarians • Human Cell Models • Geroscience

📌 KEY TAKEAWAYS

◆ Healthspan and lifespan are related goals, but improving a biological measurement is not the same as proving that people live longer.

◆ Exceptional longevity may reflect protective biology alongside disease-risk variants, as well as behavior and environmental exposures.

◆ The five projects connect discovery with functional testing. A genetic association still needs a biological explanation and follow-up experiments.

◆ Human cell models help isolate a signal; animal studies and human research test whether it matters in a more complex system.

◆ Public funding supports collaboration across disciplines and exploratory work that may not begin with a single commercial product.

◆ Shared aging mechanisms could offer opportunities to address multiple diseases. That is a research goal, not a claim that a proven universal treatment exists.

◆ A critical approach to evidence matters when evaluating claims about measuring or reversing biological age.

🎙️ THE REPROGRAM PERSPECTIVE

Longevity Biology Without the Hype. The important question is not simply whether an intervention changes a marker, but whether it produces a meaningful, reproducible benefit for people. This conversation follows the research pathway; it does not present a finished anti-aging treatment.⏱️

CHAPTERS

00:00 Can we slow aging?

01:08 Meet Dr. Nik Schork

02:01 From philosophy to longevity science

03:53 What is the Longevity Consortium?

05:24 Healthspan versus lifespan

06:31 Why team science matters07:55 Project 1: Predicting human longevity

09:23 Project 2: Lessons from long-lived species

12:46 Project 3: Centenarians and resilience

14:50 Disease-risk genes and exceptional longevity

16:20 Project 4: From genes to candidate drugs

19:04 Project 5: Testing ideas in human cells

21:42 Connecting a discovery across the consortium

24:45 The challenge of proving human benefit

26:38 What public funding makes possible

29:12 Shared aging mechanisms and the public payoff

32:13 What success could look like

35:02 Lightning round: Can aging biology be modified?

36:12 Misconceptions about publicly funded science

37:24 How to evaluate longevity claims

39:13 How the science shapes Nik’s own health choices

41:50 Closing the conversation

42:48 The ReProgram takeaway

📝 SELECTED NOTES AND REFERENCES

1. Longevity Consortium overview. Official description of the research program and its integrated approach.https://www.longevityconsortium.org/overview/

2. Longevity Consortium projects and resources. Explore the five projects and their leadership. https://www.longevityconsortium.org/

▶

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

🎬 EPISODE OVERVIEW

Could the compound in magic mushrooms influence how we age? Psilocybin research is producing intriguing findings, but changing brain activity, treating depression and extending human life are very different claims.In Episode 27, Dr. George Murphy puts psilocybin through The ReProgram Scorecard. He examines experiments in human cells and aged mice, brain imaging and plasticity studies, inflammatory markers, and clinical research on depression.The episode also explores preliminary Parkinson’s and Alzheimer’s reports, why a change in a biomarker is not the same as preventing disease, and what it would take to establish a meaningful benefit for older adults.The verdict: psilocybin deserves serious investigation. The evidence discussed does not establish human life extension or dementia prevention. Its strongest clinical argument remains mental health treatment in carefully supervised settings.

🔑 KEYWORDS

Psilocybin • Psilocin • Psychedelics • Longevity • Brain Plasticity • Depression • Inflammation • Cognitive Aging • ReProgram Scorecard

📌 KEY TAKEAWAYS

• The longevity headline needs context. More cell divisions in a dish and improved mouse survival at a study endpoint do not demonstrate longer human life.

• Brain changes are measurable. Plasticity and altered network coordination do not establish a universal neurotransmitter reset or a rejuvenated brain.• Inflammation findings vary. The marker, population and timing matter; sustained clinical benefit remains an open question.

• Preliminary observations cannot establish dementia prevention. Small uncontrolled studies and an Alzheimer’s case report provide research questions, not proof of disease reversal.

• Mental health benefits deserve their own assessment. Randomized evidence is encouraging, while durability, patient selection, support and adverse effects still matter.

• Evidence grades are claim specific. A strong plasticity score cannot fill the evidence gap for dementia prevention or human life extension.

🎙️ THE REPROGRAM PERSPECTIVE

Psilocybin’s potential is worth investigating. The next step is to establish which changes help, who benefits, how long benefits last, and what they cost in risk.Brain plasticity and network change: 4/5Mental health benefit in supervised treatment: 3/5Reducing inflammation: 2/5Preventing cognitive decline: 1/5Extending human lifespan: 1/5These are evidence grades, not treatment recommendations. They are not averaged into an overall score. The episode does not establish a longevity dosing regimen or justify self-directed use.

⏱️ CHAPTERS

00:00 Could psilocybin change how we age?

01:12 Five different claims

01:54 Cells mice and the longevity headline

03:19 What brain plasticity actually means

05:06 Human brain changes and study limitations

05:52 Neurotransmitters and the chemical reset claim

07:00 Inflammation signals and conflicting findings

09:00 Cognitive decline Parkinson's and Alzheimer's

10:58 Depression benefits durability and risks

11:59 The five part ReProgram Scorecard

13:26 What would change the evidence grades

14:03 Safety and the final verdict

📝 SELECTED NOTES AND REFERENCES1. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025. Cell and aged female mouse experiments behind the longevity discussion.https://doi.org/10.1038/s41514-025-00...

2. Psilocybin desynchronizes the human brain. Nature. 2024. Repeated imaging of brain network changes in seven healthy adults.https://doi.org/10.1038/s41586-024-07...

3. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. Published online December 2025. Mouse research on activity-dependent plasticity.https://doi.org/10.1016/j.cell.2025.1...

If you value longevity science without the hype, subscribe to The ReProgram.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 26: GLP-1 Drugs for Longevity

🎬 EPISODE OVERVIEW

A drug millions of people already take extended median lifespan by approximately 12% in older female mice. Does that change the case for GLP-1 drugs as longevity therapies?In this update, Dr. George Murphy reopens The ReProgram Scorecard to examine a new Nature study of late-life semaglutide treatment. He explores the survival findings, improvements in physical and cognitive performance, and the questions that determine how broadly we should interpret the results.How long did the control animals live? How much of the benefit came from eating less? What can a study conducted in females tell us about males—and ultimately humans?The episode also examines new research connecting calorie restriction with DNA mutation accumulation, the challenge of translating mouse biology into human outcomes, and the lessons from semaglutide’s Alzheimer’s trials.The updated assessment: stronger animal evidence and more compelling questions, while the overall grade remains B+.

🔑 KEYWORDS

GLP-1 • Semaglutide • Ozempic • Wegovy • Longevity • Healthy Aging • Calorie Restriction • Somatic Mutations • Healthspan • ReProgram Scorecard

📌 KEY TAKEAWAYS

• The survival finding deserves attention. Median lifespan increased from 742 to 834 days when semaglutide treatment began at 20 months of age and continued throughout life.

• The calorie restriction question remains open. Selected functional outcomes were compared with matched calorie restriction; lifespan was not.

• A benefit in females does not establish a female-specific effect. Males were not tested.

• Historical controls provide context. They cannot replace the controls studied alongside treated animals; replication remains essential.

• The DNA connection is a hypothesis. New calorie restriction research raises questions about mutation accumulation, but does not establish that semaglutide reduces somatic mutations.

• Human outcomes still determine the grade. Strength, mobility, nutrition, cognition, and independence remain central to evaluating longevity interventions.

🎙️ THE REPROGRAM PERSPECTIVE

This study strengthens the reason to investigate GLP-1 therapies in aging. It also sharpens the experiments we need next: replication, direct survival comparisons with calorie restriction, testing both sexes, and meaningful human outcomes.Mechanistic plausibility remains 4.5/5. Human evidence remains 3.5/5. The overall grade stays B+.My interest has increased. My standard of evidence has not changed.

⏱️ CHAPTERS

00:00 A 12% Lifespan Increase: What Does It Mean?

00:36 Revisiting GLP1 Therapies and Longevity

01:12 The New Nature Study

01:28 How Semaglutide Works

01:57 The Survival Result

03:10 The Importance of Starting Age in Treatment

03:57 The Control-Lifespan Debate

05:33 Sex Differences in Longevity Research

06:26 The Calorie Restriction Question

07:35 Calorie Restriction & DNA Mutations

09:01 Translating Mouse Findings to Humans

10:00 Lessons from the Alzheimer’s Trials

11:02 The Updated ReProgram Scorecard

📝 NOTES AND REFERENCES

1. Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. The central study discussed in this episode.https://www.nature.com/articles/s41586-026-10940-7

2. Grońska-Pęski M, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. The calorie restriction and mutation study discussed in the episode.https://doi.org/10.1016/j.cell.2026.08.013

3. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. A landmark comparison showing that late-life intervention can extend lifespan in both sexes.https://www.nature.com/articles/nature08221

If you value longevity science without the hype, subscribe to The ReProgram.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 25:

🩸 YOUR BLOOD MAY BE AGING BEFORE YOU ARE

🧠 Episode Overview

Blood aging is often overlooked, but the hematopoietic stem cells inside your bone marrow carry a decades-long history.Your blood is not just a fluid; it is a continuously renewing organ system. As the stem cells that manufacture your blood cells age, they can shift immune composition and increase susceptibility to inflammation. This process is central to understanding how systemic aging actually unfolds, moving beyond simple protein panels or biological clocks to look at the cellular machinery that sustains you.We examine the reality of clonal hematopoiesis, known as CHIP, and why it acts as a risk marker rather than a diagnosis. By separating mechanism from marketing, we clarify what parabiosis experiments and plasma exchange can—and cannot—actually achieve in human biology. Understanding blood aging helps us prioritize evidence-based outcomes over the hype of rejuvenation.Subscribe to The ReProgram for scientist-led longevity biology breakdowns, and let us know in the comments if you want a deeper look at specific plasma-related interventions.#BloodAging #LongevityScience #HealthyAging #TheReProgram

🎙️ The ReProgram Perspective

Blood aging forces us to rethink a familiar assumption. The cells circulating today may be new, but their factory - the hematopoietic stem-cell system and its marrow niche - has been shaped by decades of stress, inflammation, mutation, and repair.The biology is compelling because it connects systems that are often discussed separately: immunity, cancer risk, vascular inflammation, tissue repair, and aging. CHIP is a particularly powerful example. A mutation beginning in one stem cell can eventually influence enormous numbers of immune cells and potentially affect organs far beyond the bone marrow.But risk is not destiny, and mechanism is not treatment. CHIP should not be treated as leukemia, a mouse rejuvenation experiment should not be presented as a human anti-aging therapy, and a change in circulating proteins or an aging clock should not be confused with better function, fewer diseases, or longer life.The standard for a credible rejuvenation intervention should be transparent: disclose the intervention, pre-register the trial, define clinically meaningful outcomes, use appropriate controls, report adverse events, and publish the full results. Longevity science moves forward when fascinating biology is tested with standards strong enough to survive the hype around it.

Office Artifact

On the desk: GIANT MICROBES Blood Cells

⏱️ Chapters

00:00 The Blood Factory: Understanding Blood Cell Production

01:26 Aging Blood: Impacts on Health and Disease

02:38 The Role of Stem Cells in Blood Renewal

06:23 Immune Aging: The Complexity of Immune Responses

08:07 Clonal Hematopoiesis: A New Layer of Blood Aging

10:16 The Link Between Blood Aging and Cardiovascular Disease

12:52 Restoring Youth: Potential Strategies for Blood Rejuvenation

16:52 Parabiosis: The Young Blood Experiment

19:40 Plasma exchange: biology versus hype

21:15 Emerging Treatments: The One Generation Approach

25:09 Practical Takeaways: Managing Blood Health

Welcome to The ReProgram.

Longevity science moves a lot slower than longevity marketing.The ReProgram explores the biology of aging, longevity drugs, regenerative medicine, nutrition, exercise, biotechnology, and the emerging science that may help us live longer, healthier lives.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Understand Aging. Build Resilience. Extend Healthspan.

🎬 EPISODE OVERVIEW

Every cell in your body contains essentially the same DNA, yet a neuron behaves nothing like a skin cell. So what actually gives a cell its identity — and how permanent is that identity?In this episode, Dr. George Murphy sits down with epigenetics and cellular reprogramming expert Dr. Jose Polo to explore how cells establish identity, how that identity can be rewritten, and what reprogramming really means for aging and rejuvenation.They discuss why cellular reprogramming is not the same thing as rejuvenation, Jose’s concept of “cell elasticity,” the danger of pushing a cell so far that it loses its identity, and the possibility of using targeted cell conversion as regenerative medicine.

👤 ABOUT THE GUEST

Dr. Jose M. Polo is Director of the Adelaide Centre for Epigenetics in Australia. His research focuses on the transcriptional and epigenetic mechanisms that govern cell identity, pluripotency, cellular reprogramming, early development, and cancer. His laboratory has helped define the molecular sequence of somatic-cell reprogramming, developed strategies for direct cell-fate conversion, and pioneered human iBlastoid models of early embryonic development.Official profile: https://researchers.adelaide.edu.au/p...

🔑 KEYWORDS

Epigenetics • Cellular Reprogramming • Cell Identity • Rejuvenation • Partial Reprogramming • Yamanaka Factors • Induced Pluripotent Stem Cells • Cell Elasticity • Epigenetic Clocks • Regenerative Medicine • iBlastoids • Human Embryo Models • Longevity • Aging

📌 KEY TAKEAWAYS

• Cell identity is regulatory, not genetic. The same genome can produce radically different cell states depending on which programs are active.

• Reprogramming is not the same as rejuvenation. Resetting cellular state may erase age-associated features, but that does not automatically mean restored function.

• “Cell elasticity” may define the safe window for partial reprogramming. A cell can move away from its identity and return — until it crosses a point where that identity may no longer be recoverable.

• Preserving identity is a central safety challenge. A cell that looks younger but loses its specialized function is not a successful rejuvenation strategy.

• Cell-fate control could become medicine. Targeted reprogramming may one day convert resident cells into the cell types needed to repair damaged tissues.

• iBlastoids demonstrate extraordinary human cell plasticity. But they are experimental models — not embryos — and their biological limits matter.

🎙️ THE REPROGRAM PERSPECTIVE

Cellular reprogramming proves that cellular state is not fixed.But making an epigenetic clock move backward is not the same as making a cell healthier.The real goal of rejuvenation should be to restore function and resilience while preserving cell identity, tissue organization, and safety.In longevity science, the most meaningful endpoint is not simply whether a cell looks younger molecularly, but whether it behaves better biologically.

⏱️ CHAPTERS

02:27 Meet Dr. Jose Polo

05:34 What Makes a Cell a Neuron, Skin Cell, or Something Else?

08:15 What Is the Epigenome?

09:43 Reprogramming Is Not the Same as Rejuvenation

11:37 Does Epigenetic Change Cause Aging?

13:16 Cell Elasticity: How Far Can Identity Be Pushed?

14:39 The Danger Zone: Losing Cell Identity

16:48 Reprogramming Cells as Medicine

19:20 How Adult Cells Became Human Embryo Models

22:21 iBlastoids: What They Are — and What They Are Not

23:54 Is Aging a Failure of Cell Identity?

25:27 Can We Erase Bad Epigenetic Memory?

27:07 What We Still Do Not Understand About Reprogramming

📝 NOTES AND REFERENCES

Liu X, Tan JP, Schroder J, et al. Modelling human blastocysts by reprogramming fibroblasts into iBlastoids. Nature. 2021;591:627-632.https://doi.org/10.1038/s41586-021-03...

*If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.*

🧠 EPISODE OVERVIEW

Creatine is cheap, widely available, and backed by an unusually large body of human research. But its biology extends well beyond the gym.

The creatine–phosphocreatine system helps cells rapidly regenerate ATP when energy demand rises—in both muscle and brain.

In this episode, we examine the evidence for creatine and muscle preservation, cognition and brain resilience, kidney safety, dosing, and emerging high-dose brain protocols.

And most importantly: does any of this make creatine a true longevity supplement?

Creatine goes through The ReProgram Scorecard.

Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🔑 KEYWORDS

Creatine • Creatine Monohydrate • Longevity • Healthspan • Muscle • Strength • Resistance Training • Brain Health • Cognition • ATP • Phosphocreatine • Kidney Health • Healthy Aging

🧠 KEY TAKEAWAYS

•

Energy: Creatine helps buffer cellular energy by supporting rapid ATP regeneration.

•

Muscle: The strongest evidence is for strength and performance. Combined with resistance training, creatine can improve strength and augment gains in lean tissue.

•

Brain: Cognitive evidence is promising but less established. Benefits may be most relevant when the brain is under energetic stress.

•

Alzheimer’s: Creatine is not proven to prevent or treat Alzheimer’s disease. Higher-dose brain protocols remain experimental.

•

Kidneys: Safety data in healthy individuals are reassuring. Creatine can raise serum creatinine without necessarily indicating kidney damage.

•

Dose: For most people, 3–5 g/day of creatine monohydrate is the conventional evidence-based approach. Loading is optional.

•

Longevity: Healthspan evidence is not lifespan evidence. There is currently no randomized human evidence that creatine extends human lifespan.

🎙️ THE REPROGRAM PERSPECTIVE

Creatine combines compelling biology, strong human evidence for specific outcomes, low cost, and reassuring safety—without proving that it slows human aging.

Sometimes the most interesting intervention is not the newest or most expensive one.

📊 THE REPROGRAM SCORECARD: CREATINE

⚙️ Mechanistic Plausibility: A
💪 Muscle & Performance Evidence: A
🧠 Brain & Cognitive Evidence: B
🛡️ Safety: A−
💰 Cost & Accessibility: A+
⏳ Direct Longevity Evidence: C

🏆 FINAL REPROGRAM GRADE: A−

Verdict: Strong biology, unusually good human evidence for muscle and performance, reassuring safety, low cost, and an increasingly interesting brain story. The longevity claim itself remains unproven.

⏱️ CHAPTERS

00:00 Creatine: The Longevity Supplement Hiding in Plain Sight?
01:58 Understanding Creatine: Mechanisms and Benefits
03:56 Scorecard #1: Muscle & Performance
07:07 Scorecard #2: The Brain & Cognition
09:57 Creatine & Alzheimer’s Disease
11:41 Scorecard #3: Safety & the Kidney Question
14:39 Other Side Effects
15:13 How Much Creatine Should You Take?
16:33 What About Higher Doses for the Brain?
17:46 The Final ReProgram Scorecard
19:06 Final Thoughts: Creatine's Role in Longevity

If you value longevity science without the hype, subscribe to The ReProgram.

#Creatine #LongevityScience #HealthyAging #TheReProgram

🐾 EPISODE OVERVIEW

This episode asks a deceptively simple question: Can we actually help our dogs and cats live longer, healthier lives?We explore why companion animals are unusually powerful models of aging, why “one dog year equals seven human years” is biologically wrong, what the Dog Aging Project is revealing, what pet owners can reasonably do today, and where emerging interventions like rapamycin, canine longevity drugs, AIM therapy, and gene therapy fit into the evidence.

🔑 KEYWORDS

Pet longevity, dog aging, cat aging, healthspan, Dog Aging Project, rapamycin, TRIAD Trial, Loyal, feline kidney disease, AIM/CD5L, gene therapy, pet nutrition, body condition, muscle preservation, geroscience, comparative aging, healthy aging, veterinary medicine

💡 KEY TAKEAWAYS

• Dogs and cats may be powerful real-world models of aging because they share our homes, environments, behaviors, and many naturally occurring diseases.

• Dog years are not human years. Aging rates change throughout life and vary dramatically by breed and body size.

• For most pets, the strongest longevity strategies today remain surprisingly conventional: appropriate body composition, good nutrition, movement, muscle preservation, dental care, pain management, preventive medicine, and early disease detection.

• Rapamycin, dedicated canine longevity drugs, AIM therapy, and gene therapies are scientifically exciting—but they remain at different stages of experimental validation.

• Healthspan matters more than lifespan at any cost. More time only matters if we preserve the experiences that make an animal recognizably itself.

🎙️ THE REPROGRAM PERSPECTIVE

Pet longevity is a perfect example of why we need to separate mechanistic plausibility from meaningful outcomes.A supplement that changes a biomarker is not necessarily extending healthspan. An intervention that treats one age-related disease is not necessarily slowing aging throughout the entire organism. And an exciting mouse study is not a reason to start experimenting on your pet.

Mechanism over marketing. Evidence over anecdotes. Healthspan over lifespan at any cost.

OFFICE ARTIFACT

On the desk: Tut, 3 year old Hairless Peterbald Sphinx: https://www.instagram.com/tutandbeebe.sphynx/

⏱️ CHAPTERS

0:00 Can Our Pets Live Longer?

2:10 Welcome: The Science of Pet Longevity

3:52 Why Pets Are Living Aging Studies

7:58 The Myth of “Dog Years”

10:57 Inside the Dog Aging Project

14:19 What Pet Owners Can Do Right Now

16:56 Is There a Longevity Diet for Pets?

20:08 Oral Health and Preventative Care in Pets

21:40 Rapamycin and the TRIAD Trial

23:27 The First Canine Longevity Drugs?

24:30 AIM Therapy and Feline Kidney Disease

27:48 Gene Therapy for Aging-Related Disease

29:06 Purina and the Pet Longevity Industry

31:02 The ReProgram Pet Longevity Scorecard

33:54 Tut, Healthspan & Why More Time Matters

🧠 Episode Overview

Mitochondria are known as the powerhouses of the cell—but energy production is only part of their story.In this episode of The ReProgram, Dr. George Murphy speaks with mitochondrial biologist Dr. Stefan Isaac about mitochondrial DNA, heteroplasmy, stress signaling, mitophagy, genome editing, and the possibility of transferring healthy mitochondria into damaged or aging cells.They also explore a central longevity paradox: more mitochondrial activity may not always be better. Long-lived organisms and centenarian-derived cells may preserve health through lower baseline activity, greater efficiency, and a stronger capacity to respond to stress.Could we replace aging mitochondria, repair mutant mitochondrial DNA, or generate rejuvenated mitochondria from reprogrammed cells? And would a young mitochondrion remain healthy inside an old cellular environment?

🔑 KeywordsStefan Isaac, mitochondria, mitochondrial aging, mitochondrial DNA, heteroplasmy, mitophagy, mitochondrial transfer, mitochondrial transplantation, genome editing, cellular reprogramming, centenarians, longevity, healthspan, ReProgram Podcast

🧠 Takeaways

• Mitochondria regulate metabolism, stress signaling, and cell fate—not just energy production.

• More mitochondrial activity is not necessarily better; longevity may depend on efficiency, adaptability, and recovery.

• Exercise remains the strongest evidence-based strategy for supporting mitochondrial function.

• Transplanted mitochondria remain dependent on the recipient cell’s nuclear genome and cellular environment.

• Genome editing and selective removal of mutant mitochondrial DNA may transform future mitochondrial medicine.

🎙️ The ReProgram Perspective

Resilience over raw output. Function over biomarkers. Mechanism over marketing.The longevity industry often assumes that more energy, more mitochondrial biogenesis, and more metabolic activity must be better. This episode challenges that assumption.A mitochondrion should not be judged only by ATP production, membrane potential, NAD levels, or quantity. The more important question is whether the cell can adapt to stress, remove damaged organelles, preserve function, and recover.Perhaps the goal is not to make mitochondria work harder. Perhaps the goal is to help them remain efficient, responsive, and resilient.

Office Artifact:

On the desk: Giant Microbes: Cell Organelles

Chapters

03:35 Introducing Dr. Stefan Isaac

04:26 Beyond the Powerhouse

07:19 Mitochondrial Aging and DNA

10:58 Interventions and the Longevity Paradox

17:33 Mitochondrial Transfer and Transplantation

22:44 Reprogramming and Genome Editing

29:04 The Future—and What You Can Do Now

🧠 Episode Overview

Metformin is inexpensive, widely prescribed, and supported by decades of clinical experience. It is also one of the most frequently discussed drugs in longevity medicine.But does metformin actually slow human aging?In this episode, Dr. George Murphy puts metformin through The ReProgram Scorecard, examining its biological mechanisms, human evidence, safety, accessibility, and likely value for people with—and without—metabolic disease.The central distinction is context. Metformin can delay diabetes in people at elevated metabolic risk, but evidence that it extends lifespan or broadly prevents age-related disease in metabolically healthy adults remains limited.

Final ReProgram Grade: B−

For healthy-adult longevity use: C+

🔑 Keywords

Metformin, metformin and longevity, biological aging, healthspan, diabetes prevention, insulin resistance, prediabetes, anti-aging drugs, longevity medicine, ReProgram Scorecard, Dr. George Murphy

🧠 Key Takeaways

• Metformin is an established metabolic drug, not a proven anti-aging medication.

• Its mechanisms intersect with energy sensing, glucose regulation, inflammation, mitochondrial biology, AMPK, and mTOR.

• The strongest benefits are seen in people with diabetes, prediabetes, insulin resistance, or elevated metabolic risk.

• Evidence that healthy, insulin-sensitive adults benefit from taking metformin for longevity is weak.

• Long-term follow-up found that metformin prevented diabetes but did not significantly reduce all-cause, cardiovascular, or cancer mortality.

• The key question is not whether metformin affects aging-related pathways. It is whether it improves meaningful outcomes in the right population.

🎙️ The ReProgram Perspective

Mechanism over marketing.Evidence over anecdotes.Trade-offs over hype.Metformin deserves respect as a safe, inexpensive, and valuable metabolic medicine.But correcting abnormal metabolism is not necessarily the same as slowing aging in someone whose metabolism is already healthy.The stronger the underlying metabolic dysfunction, the greater the potential benefit. For healthy adults seeking a general longevity drug, the evidence is not yet compelling.

📊 The ReProgram Scorecard

Mechanistic plausibility: 4 / 5

Human longevity evidence: 2.5 / 5

Likely benefit — metabolic-risk populations: 4 / 5

Likely benefit — metabolically healthy adults: 1.5 / 5

Safety and downside risk: 4 / 5

Cost and accessibility: 5 / 5

Longevity hype risk: Moderate–High

Healthy-adult longevity use: C+

Final ReProgram Grade: B−

Verdict: An excellent metabolic drug and plausible geroscience tool—but not a proven longevity drug for healthy people.

Chapters

00:26 What Metformin Does

00:54 Is Metformin Really a Longevity Drug?

02:37 Understanding Metformin: Mechanisms and Uses

04:48 Evaluating Human Evidence for Metformin

07:46 Magnitude of Likely Benefits of Metformin

08:55 Safety and Potential Downsides of Metformin

10:54 Who May Benefit Most from Metformin

12:28 Cost, Accessibility, and Longevity Hype Risk

13:42 Final ReProgram Grade

📝 Notes and References

1. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes With Lifestyle Intervention or Metformin. New England Journal of Medicine. 2002;346:393–403. Metformin reduced diabetes incidence by 31%, compared with 58% for intensive lifestyle intervention. PubMed: https://pubmed.ncbi.nlm.nih.gov/11832...

2. Lee CG, et al. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021. PubMed: https://pubmed.ncbi.nlm.nih.gov/34697...

3. Salive ME, et al. Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes. JAMA. 2026. DOI: 10.1001/jama.2026.8492.

4. Walton RG, et al. Metformin Blunts Muscle Hypertrophy in Response to Progressive Resistance Exercise Training in Older Adults: The MASTERS Trial. Aging Cell. 2019.

🧠 Episode Overview

What if your age on paper is not the number that matters most?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Raghav Sehgal at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Sehgal discusses his work analyzing dozens of putative longevity interventions across epigenetic clocks, why DNA methylation data are uniquely useful for cross-study harmonization, and why some interventions may move aging biomarkers only in specific biological contexts.The central message: aging clocks are not magic answers, but they may become powerful instruments for separating longevity science from longevity marketing.

🔑 Keywords

Raghav Sehgal, biological age, chronological age, aging clocks, epigenetic clocks, biomarkers of aging, longevity interventions, geroscience, AI and aging, artificial intelligence, rapamycin, metformin, hronic inflammation, lifestyle interventions, exercise, diet, supplements, follistatin gene therapy, clinical translation, precision longevity, ReProgram Podcast, Dr. George Murphy

🧠 Takeaways

• Chronological age tells us how long we have been alive; biological age attempts to measure how fast health risk and physiological decline are progressing.

• If aging cannot be quantified, it becomes difficult to test whether an intervention is actually modifying aging biology.

• Epigenetic clocks are especially useful for large cross-study analyses because DNA methylation platforms are relatively standardized compared with many other omics technologies.

• Dr. Sehgal describes a major harmonization effort across clinical trials and observational studies to ask which interventions move aging biomarkers.

• Some surprising signals came from anti-retroviral therapy and inflammation-targeting drugs, raising questions about retrotransposons, immune activation, and chronic inflammation in aging.

• Context matters: an intervention may shift aging biomarkers in one group, disease state, tissue, or organ system but not another.

• Rapamycin remains promising in model organisms, but the human biomarker evidence is still more complicated and less definitive than the hype suggests.

• AI may accelerate longevity science by cleaning messy datasets, mapping aging trajectories, and helping explain why a biological age score moved.

• The future of longevity medicine will depend on better biomarkers, longitudinal data, careful interpretation, and avoiding one-size-fits-all claims.

🎙️ The ReProgram Perspective

This episode is a reminder that longevity science is entering a measurement era. The key question is no longer only whether an intervention sounds plausible, works in mice, or has a compelling mechanism. The harder question is whether it measurably changes human aging biology in the right person, tissue, and context.The most important idea from this conversation may be that biological age is not a single magic number. It is a window into complexity. The promise of the field is not just to tell someone they are “younger” or “older” than expected. The promise is to understand why that signal is changing and what, if anything, can be done about it.

Chapters

02:33 Introduction from the Systems Aging GRC

03:02 Biological Age vs Chronological Age

04:28 Testing 51 Longevity Interventions

06:20 Why Epigenetic Clocks?

08:12 Anti-Retroviral Therapy, Retrotransposons, and Aging

10:36 The Role of Inflammation in Aging

12:23 What Counts as a True Longevity Signature?

15:08 Rapamycin, Humans, and the Evidence Gap

16:31 Surprising Findings From the Study

18:19 Aging Clocks in the Clinic

19:47 AI, Big Data, and Longevity Science

22:32 Raghav’s Personal Health Transformation

Notes

Dr. Sehgal's Website: https://www.raghav-sehgal.com/

Dr. Sehgal's 51 Interventions Paper: https://www.biorxiv.org/content/10.1101/2024.10.22.619522v1.full

TranslAGE: https://www.translage.io/

🧠 Episode Overview

What if aging is shaped not only by what you eat, how much you exercise, or which genes you inherit — but also by when your body does things each day?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Mimi Shirasu-Hiza at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Shirasu-Hiza is a Professor of Genetics and Development at Columbia University and an international expert in circadian gene regulation, aging, and health.This conversation explores circadian rhythms as daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior — and why disruption of those rhythms through shift work, jet lag, irregular sleep, or mistimed eating may affect metabolism, cardiovascular risk, obesity, cancer risk, and aging biology.A major focus is time-restricted eating: not simply eating less, but aligning eating and fasting with the body’s active and resting phases. Dr. Shirasu-Hiza discusses work in fruit flies showing that time-restricted eating can extend lifespan and preserve youthful oscillations in genes involved in metabolism, protein translation, immune defense, stress response, and other core biological programs.

🔑 Keywords

Circadian rhythms, circadian clock, biological rhythms, time-restricted eating, intermittent fasting, caloric restriction, meal timing, fasting window, overnight fasting, metabolism, cardiovascular disease, obesity, cancer risk, aging biology, longevity science, geroscience, exercise, healthspan, resilience, ReProgram Podcast, Dr. George Murphy

🧠 Takeaways

• Circadian rhythms are daily, approximately 24-hour oscillations in gene expression, tissue function, and behavior.

• The circadian clock is not just about sleep; it helps coordinate transcription, metabolism, feeding, fasting, activity, tissue function, and recovery.

• Circadian disruption is associated with cardiometabolic disease, obesity, and cancer risk, especially in shift workers, frequent travelers, and others whose activity occurs during the usual rest phase.

• Time-restricted eating is different from caloric restriction. It focuses on when food is consumed, not necessarily how many calories are consumed.

• Aging may involve loss of rhythmic gene expression. Time-restricted eating preserved youthful oscillations in genes linked to metabolism, protein translation, immune defense, defense response, and stress response.

• Meal timing may help reset circadian rhythms during jet lag, suggesting that food can act as a timing cue for the body clock.

🎙️ The ReProgram Perspective

This episode is a reminder that longevity science is not only about molecules, supplements, or single interventions. It is also about biological organization.Circadian biology reframes aging as a problem of timing. Genes, metabolism, immunity, tissue repair, behavior, feeding, and fasting are not static processes. They are coordinated across the day.Dr. Shirasu-Hiza’s work in flies is powerful because it shows that preserving youthful gene-expression rhythms may be linked to lifespan and health. But the translation to humans requires care. The takeaway is not that everyone should follow one rigid fasting window. The takeaway is that timing is biology — and maintaining rhythm may be one underappreciated part of resilience, recovery, and healthy aging.

Chapters

00:00 Can Meal Timing Slow Aging?

02:16 Introduction from the Systems Aging GRC

03:08 What Are Circadian Rhythms?

03:46 Shift Work, Jet Lag, and Health Risk

04:30 Circadian Disruption and Cancer Risk

04:59 Time-Restricted Eating vs Intermittent Fasting

05:29 Eating Windows and Overnight Fasting

06:20 Why Fruit Flies Are Powerful Aging Models

07:17 The “Keep Me Young” Genes

08:47 Fasting, Foraging, and Exercise-Like Behavior

09:37 Can Drugs Mimic Circadian Benefits?

10:37 Meal Timing and Jet Lag

12:03 Calories, Diet Type, and Individual Differences

13:03 Closing Reflections

🧠 Episode Overview

What if “biological age” as a single number is the wrong way to think about aging?In this episode of The ReProgram, Dr. George Murphy sits down with Dr. Rich Miller at the Gordon Research Conference Systems Aging Meeting in Maine.Dr. Miller is a Professor of Pathology at the University of Michigan and one of the leaders of the Interventions Testing Program, the gold standard for testing longevity interventions in genetically diverse mice.This conversation challenges some of the biggest assumptions in longevity science: biomarkers of aging, cellular senescence, the search for one cause of aging, and the idea that mouse lifespan results automatically translate into human recommendations.The central message:Aging is not one pathway, one biomarker, or one number.The real question is not simply what causes aging.The real question is what can postpone many forms of age-related decline at the same time.

🔑 Keywords

Richard Miller, Interventions Testing Program, ITP, aging biology, longevity science, geroscience, biological age, biomarkers of aging, aging-rate indicators, anti-aging drugs, geroprotectors, rapamycin, acarbose, ergothioneine

🧠 Takeaways

• Aging should not be reduced to one cause, one pathway, one biomarker, or one biological age number.

• Rich Miller argues that the key question is not what causes aging, but what postpones many forms of age-related damage at once.

• Lifespan is useful because it is definitive, but a true anti-aging drug should also delay multiple forms of functional decline.

• Most proposed longevity interventions fail when tested rigorously.

• Biomarkers of aging and aging-rate indicators are not the same thing.

• A biomarker may change with age. An aging-rate indicator should tell us whether aging is moving faster or slower.

• “Biological age” as a single number may hide important differences across tissues, systems, and disease risks.

• Ergothioneine is intriguing in slow-aging mice, but it is not yet clear whether it is causal or simply a marker of a broader metabolic state.

• Sex differences matter. Some interventions work in male mice but not female mice.

• Rapamycin and acarbose are exciting in mice, but they are not proven human longevity drugs.

• No drug has yet been proven to extend human lifespan by slowing aging itself.

🎙️ The ReProgram Perspective

The ReProgram lens is simple:Mechanism over marketing.Outcomes over biomarkers.Trade-offs over hype.This episode is a reminder that longevity science needs both ambition and restraint.A compound that changes a biomarker has not necessarily slowed aging.A drug that extends lifespan in mice is not automatically safe or effective for humans.And a single “biological age” number may not capture the complexity of how real people age.Rich Miller’s message is not that aging biology is impossible.It is that the field has to be precise about what the data actually prove.The future of longevity science depends on rigorous testing, better endpoints, genetic diversity, sex-specific biology, and a clear distinction between promising mechanisms and proven outcomes.

Chapters

00:00 Are There Really Biomarkers of Aging?

02:09 Dr. Rich Miller’s Origin Story

03:24 How His Views on Aging Changed

04:21 How Rich Miller Defines Aging and Its Complexities

05:48 The Interventions Testing Program (ITP)

07:31 What Is a True Anti-Aging Drug?

08:37 Longevity Signatures and Metabolites

10:33 The Role of Ergothionine in Aging

13:17 Biomarkers vs Aging-Rate Indicators

16:26 Sex Differences in Aging Research

19:11 The Importance of Genetically Diverse Models

22:09 Advocating for Aging Research

23:45 Aging Research and Cancer

25:19 Disease Silos in Science

27:11 Rich Miller’s Own Longevity Habits

29:51 The Risk of Rapamycin Self-Experimentation

Notes

The Interventions Testing Program (ITP): https://www.nia.nih.gov/research/dab/interventions-testing-program-itp

Dr. Rich Miller Lab: https://www.richmillerlab.com/

🧠 Episode Overview

Are GLP-1 agonists longevity drugs?Not weight loss drugs.Not cosmetic drugs.Not simply appetite drugs.In this episode of The ReProgram, Dr. George Murphy launches a new recurring format: The ReProgram Scorecard — a science-first framework for grading popular longevity interventions through the same lens every time:Mechanistic plausibility.Human evidence.Magnitude of likely benefit.Safety and downside risk.Who may benefit most.Who should be cautious.Cost and accessibility.Longevity hype risk.And the final ReProgram grade.

🔑 Keywords

GLP-1 agonists, GLP-1 and longevity, semaglutide, Ozempic, tirzepatide, metabolic health, healthspan, aging biology, inflammation, brain aging, cognitive decline, neuroinflammation, neuronal resilience, longevity medicine, geroscience, The ReProgram Podcast, Dr. George Murphy.

🧠 Takeaways

• GLP-1 agonists should not be understood only as weight-loss drugs.

• GLP-1 agonists are not yet proven to slow biological aging, extend lifespan, reverse aging clocks, prevent frailty, or broadly preserve function across all older adults.

• The magnitude of likely benefit is highly context-dependent. People with obesity, insulin resistance, type 2 diabetes, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction may benefit most.

• For metabolically healthy people using GLP-1 agonists purely as longevity hacks, the benefit is much less clear.

• Safety matters. These are real drugs with real side effects, and they should not be treated as casual wellness supplements.• Lean mass preservation is critical. Weight loss without attention to resistance training, protein intake, and muscle maintenance may undermine long-term resilience, especially in older adults.

🎙️ The ReProgram Perspective

The ReProgram lens is clear:Mechanism over marketing.Evidence over anecdotes.Trade-offs over hype.GLP-1 agonists are not magic. They are not proven anti-aging drugs. And they should not be marketed as universal longevity tools. But they also should not be dismissed as simple weight-loss drugs.

📊 The ReProgram Scorecard

Mechanistic plausibility: 4.5 / 5Strong aging-relevant biology: metabolism, inflammation, cardiovascular risk, immune tone, and potentially neuronal resilience.

Human evidence: 3.5 / 5 Strong for cardiometabolic outcomes. Promising but incomplete for longevity, resilience, and cognitive decline.

Magnitude of likely benefit:4 / 5 in high-risk metabolic populations. 2.5–3 / 5 for broad longevity use.

Safety and downside risk: 3 / 5 Useful drugs, but real side effects, medical supervision required, and muscle preservation matters.

Who may benefit most: People with obesity, type 2 diabetes, insulin resistance, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction.

Who should be cautious: People with low muscle mass, frailty, eating disorders, certain GI or pancreatic/gallbladder risks, pregnancy considerations, relevant endocrine cancer risks, or anyone using unregulated versions.

Cost and accessibility: 2 / 5 Major barrier.

Longevity hype risk: High The biology is real, but the public narrative is ahead of the evidence.

Final ReProgram Grade: B+

Chapters

00:00 Are GLP-1 Agonists Longevity Drugs?

01:03 Introducing The ReProgram Scorecard

02:02 What Are GLP-1 and Incretin-Based Therapies?

03:33 Mechanistic Plausibility: Why GLP-1 Biology Matters for Aging

06:27 Human Evidence: Cardiometabolic Healthspan vs. Longevity Proof

08:45 Magnitude of Benefit: Who Has the Most Room to Improve?

10:52 Safety, Side Effects, and Lean Mass Concerns

14:04 Identifying Who May Benefit Most

15:09 Who Should Be the Most Cautious in Using These Drugs?

16:18 Cost and Accessibility Challenges

17:20 Longevity Hype Risk

19:34 Potential Cognitive Benefits of GLP1 Agonists

22:17 Final ReProgram Scorecard for GLP1 Agonists

24:10 Final Verdict on GLP1 Agonists and Future Directions

ReProgram Episode 14

AI and Longevity: Hype, Hope, and the Biology of Aging

🧠 Episode Overview

What if your doctor could look at your bloodwork, medical history, genome, proteins, metabolites, microbiome, and health trajectory - and tell you more than whether you are sick today?Can artificial intelligence decode human aging?AI will not magically cure aging. It will not replace biology. And it will not tell us exactly how to live forever.But it may help us do something incredibly important:See patterns in human aging that are too complex for the human mind to detect alone.In this episode of The ReProgram, Dr. George Murphy explores the real promise of AI in longevity science — and where the hype goes wrong.Aging is not one gene, one pathway, one biomarker, or one supplement. Aging is a moving, interacting network across time.That is why AI matters.But prediction is not understanding.A biomarker is not an outcome.And an AI-generated recommendation is not automatically personalized medicine.The future is not AI instead of biology.It is AI plus biology.

🧠 Takeaways

• AI will not magically cure aging, but it may become one of the most powerful tools for organizing biological complexity.

• Aging is not a single pathway, gene, biomarker, or intervention. It is a dynamic network that changes over time.

• The most useful question is not simply whether AI can predict aging, but whether AI can help us understand, measure, and eventually preserve resilience.

• AI can identify patterns across massive datasets, but pattern recognition is not the same as biological truth.

• Prediction is not understanding. An AI model may predict risk without explaining the mechanism behind that risk.

• Bad data plus powerful AI does not create truth. It creates confident noise.

• AI-generated health recommendations are not automatically personalized medicine; they may be personalized guesses delivered with confidence.

• The future of longevity science is not AI instead of biology. It is AI plus biology.

• The winning formula is: AI plus longitudinal human data plus functional biology plus clinical outcomes.

🎙️ The ReProgram Perspective

The ReProgram lens is clear:AI is a tool.Biology is the reality.Health is the outcome.AI should not be dismissed as hype, because it is already changing scientific work. It is being used in data analysis, bioinformatics, coding, experimental design, literature review, hypothesis generation, logic checking, and the interpretation of large-scale biological datasets.But AI should also not be treated as magic.In longevity science, a correlation is not enough. A biomarker can correlate with age and still not drive aging. A biological age number can move after an intervention and still not prove that healthspan improved. A predictive model can sound authoritative and still fail to explain what is happening biologically.That is why this episode argues for grounded optimism.Be excited about AI.Be skeptical of overclaims.Demand validation.Ask whether predictions connect to mechanisms.Ask whether mechanisms connect to outcomes.Ask whether outcomes improve human lives.The future is not AI replacing biology.The future is AI helping us ask better biological questions — and then testing those questions in the lab and the clinic.

Office Artifact:

On the desk: GATTACA on DVD; 1997; IMDb7.7

Chapters

00:00 The Promise of AI in Longevity

02:02 Why AI and Longevity are Both Exciting and Overhyped

03:36 AI in the Lab, Not Science Fiction

05:01 Aging is a Network That Changes Over Time

06:35 Patterns in Aging and AIs Role

09:11 Understanding Mechanisms Behind Predictions

12:04 AI + Experimentation = Success

14:37 The Hype vs. Reality of AI in Longevity

17:18 The Future of AI in Longevity Medicine

18:54 Personalizing Longevity with AI

21:07 The Future: AI and Human Biology Connection